Interesting article I stumbled onto. HER2 surface antigen is up-regulated on blasts of approximately one-third of adult B-ALL and is associated with chemoresistance in those patients. In ph2, only 13% had ORR to single agent trastuzumab, with no CR. T-DM1 will probably have better efficacy if T doesn't promote cell death in ALL cells.
I now remember why I have not been too excited about IMGN and SGEN's CD19 ADCs. Blinatumumab, the BITE that got acquired from Amgen has very high CRs, and none of the toxicity of the chemo part of ADCs. I was invested for awhile until buyout but now I can't even remember the name of the company. And before I finished typing that last sentence, my system was able to extract it from the deep recesses of my super cluttered brain: Micromet. MITI. The mighty mite.
Good luck to all.
50% spike if it's Roche or Novartis. I hope... Adding on Mon since the tapir decided to ease up on my holdings. Ahh, the tapir. It's not completely done toying with the market yet that I might as well be done and over with that animal. At least the budget debate had left the picture.
Lighten up, John. After all, we're all gonna make money here. I don't see the real need for the PR because they could have just waited for the outcome of the bidding process. I think they just wanted to brag a little, or a lot, that there are many parties interested in the Isonep rights, and that the pps should not be tanking, but rising. It was a good move on their part to keep holders excited. Disappointing though that pps didn't go up and stay much higher.
It's the fed "tapir" again, outrunning the bulls. Biotechs driven up momentarily to be driven down again. Down 10% the last 2 weeks.
I've been adding at this low 4's. I still have the sub-4s that I bought during the last drop, sold the ones I bought at 5s in the recent pop, now buying again little by little. Will buy much more if manipulators use the Pfizer agreement angle to pull this down again. Meanwhile, ASH is bringing some excitement to the blood onco stocks. Now, what will our legislators do to the stock market come January?
This is a buy and hold since they are still into ph2, not approval like VNDA. But encouraging ASH update will drive this up, followed by ph2 conclusions in ASCO 2014. A partner would be nice after that. Of course, you could play it as buy, sell, buy, sell, too, with those anticipated events.
I was long VNDA but sold too early after their schizo drug approval, bec I thought an alarm clock will work as well for the blind.
Anyway, best of luck.
And I tried to add in the 40 something after reading the ASH abstracts and asked too low! So many appetizers and main courses being offered at ASH!